

BOARD OF MEDICINE

Open Session Agenda

July 27, 2022
8:30 am

VIRTUAL MEETING NOTICE

Currently, all board meetings will be held virtually during the declared public emergency.

Information on how to access the public portion of the meeting is listed below:

Join by Web:

<https://dcnet.webex.com/dcnet/j.php?MTID=m7f823658b3b1e1556a59c90709042b04>

Join by Phone:

+1-202-860-2110 United States Toll (Washington D.C.)

1-650-479-3208 Call-in number (US/Canada)

Access Code:

160 487 2313

BOARD MISSION STATEMENT:

“To **protect** and enhance the health, safety, and well-being of District of Columbia residents by **promoting** evidence-based best practices in health regulation, high standards of quality care and implementing policies that **prevent** adverse events.”

The Open Session Agenda continues on the next page with the ‘Board Meeting Participants’.

BOARD MEETING PARTICIPANTS:

BOARD MEMBERS:	
Andrea Anderson, MD (AA)	
William Strudwick, MD (WS)	
Jeffrey Smith, MD (JS)	
Archie Rich (AR)	
Vikisha Fripp, MD (VF)	
Christopher Raczynski, MD (CR)	
Konrad Dawson, MD (KD)	
Aeva Gaymon-Doomes, MD (AGD)	
Karen George, MD (KG)	
Asad Bandealy, MD (AB)	
VACANT (Physician Member)	
VACANT (Physician Member)	
VACANT (Consumer Member)	
VACANT (Consumer Member)	
VACANT (Consumer Member)	
BOARD STAFF:	
Arian Gibson, MS – Interim Associate Director	
Aisha Nixon – Executive Director	
Lisa Robinson – Health Licensing Specialist	
Mary Harris – Health Licensing Specialist	
Angela Braxton – Health Licensing Specialist	
Charles Annor – Health Licensing Specialist	
Kimberly Quickley – Health Licensing Specialist	
Gregory Scurlock – Compliance Officer	
Emilia Moran – Investigator	
LEGAL STAFF:	
Suzanne Fenzel, Esq. – Board Attorney Advisor	
Ajay Gohil, Esq. – Board Attorney Advisor	

The Open Session Agenda continues on the next page with the ‘Call to Order’.¹

¹ The order in which the following agenda items are listed does not necessarily reflect the order in which the items were discussed during the meeting.

CALL TO ORDER		
OS-22-07-01	<u>INTRODUCTIONS</u>	
ALL	<p>A. BOARD MEMBERS</p> <p>B. BOARD STAFF</p>	

APPROVAL OF MINUTES, CONSENT AGENDA, BOARD POLICIES, AND STAFF REPORTS		
OS-22-07-02	<u>BOARD/DEPARTMENT REPORT</u>	AN
ALL	<p>A. BOARD CHAIR’S REPORT</p> <p>B. INTERIM ASSOCIATE DIRECTOR’S REPORT</p> <p>C. EXECUTIVE DIRECTOR’S REPORT</p> <p style="margin-left: 20px;">i. DC Health Updates The Executive Director will provide an update on the District’s response to public health issues/concerns.</p> <p style="margin-left: 20px;">ii. Upcoming Renewals The Executive Director will provide an update on the upcoming renewal cycle, workforce survey, and the requirements.</p> <p style="margin-left: 20px;">iii. Board Vacancies/MOTA Update The Executive Director will provide an update on current Board vacancies.</p> <p style="margin-left: 20px;">iv. Licensure Census The Executive Director will provide an update on the current licensure census in the District.</p> <p>D. BOARD ATTORNEY’S REPORT</p> <p>E. OFFICE OF GOVERNMENT RELATION’S REPORT</p>	
OS-22-07-03	<u>OPEN SESSION MINUTES</u>	AN/CA
ALL	<p>Board Action: Consideration of the Open Session minutes from the June 29, 2022 meeting.</p> <p>Background:</p>	

	The Open Session Minutes are a record of the Board’s past meeting(s), describing the events, list of attendees; a statement of the issues considered and related responses or decisions of the Board.	
OS-22-07-04 ALL	<p><u>OPEN CONSENT AGENDA</u></p> <p>Board Action: Consideration of the current open Consent Agenda items for purposes of review and/or ratification of Board actions taken since the last Board meeting.</p> <p>Background: The Open Consent Agenda is a record of the decisions and/or actions taken by the Board or its staff since the last meeting of the Board.</p>	
OS-22-07-05 ALL	<p><u>BOARD POLICIES</u></p> <p>A. <u>FSMB: Professional Expectations Regarding Medical Misinformation and Disinformation</u></p> <p>Board Action: Consideration of FSMB Approved Disinformation statement and determine whether to develop similar policy for the DC Board of Medicine.</p> <p>Background: At the annual FSMB conference in April 2022, the FSMB House of Delegates adopted a policy regarding professional expectations regarding medical misinformation and disinformation. FSMB recommends that state medical boards adopt a policy that clarifies board expectations regarding the dissemination of misinformation and disinformation.</p> <p>B. <u>FSMB Position Statement: Treatment of Self, Family Members and Close Relations</u></p> <p>Board Action: Consideration of FSMB position statement regarding treatment of self, family members, and close relations and determine whether to adopt or develop a policy regarding this matter.</p> <p>Background: In May 2022, FSMB issued a position statement that sets expectations related to the provision of treatment of oneself, one’s family members, and close personal relations.</p>	AA

The Open Session Agenda continues on the next page with 'Presentations, Misc. Items for Discussion, and FYI'.



PRESENTATIONS, MISC. ITEMS FOR DISCUSSION AND FYI

<p>OS-22-07-06</p> <p>ALL</p>	<p><u>REQUEST FOR APPROVAL OF CONTINUING EDUCATION</u></p> <p>Board Action: To review the request from DC Health Community Health Administration (CHA) for Board approval of continuing education for COVID-19 Peer to Peer training.</p> <p>Background: CHA has developed an interactive training opportunity aimed at increasing healthcare providers' confidence and knowledge regarding the COVID-19 vaccinations. The training would be offered on a virtual platform and issue 1.5 continuing education units.</p>	<p>AN</p>
<p>OS-22-07-07</p> <p>ALL</p>	<p><u>PRESENTATION COMMUNITY HEALTH ADMINISTRATION PRIMARY CARE OFFICE</u></p> <p>Board Action: To listen to a short presentation from the Primary Care Office Director, Khalil Hassam regarding the Workforce Survey and the Health Professional Loan Repayment Program (HPLRP).</p> <p>Background: Mr. Hassam will provide a licensure survey update and information about the HPLRP.</p>	<p>AN</p>
<p>OS-22-07-08</p> <p>ALL</p>	<p><u>REQUEST FOR BOARD OPINIONS</u></p> <p>Board Action: To provide an opinion on the question presented by the Executive Office of the Mayor (EOM).</p> <p>Background: The EOM, through DC Health General Counsel, has asked the BOM to opine on whether or not:</p> <ul style="list-style-type: none"> (1) A physician can mail Mifeprex (mifepristone) and misoprostol to a patient to end an early pregnancy; and (2) Is it the same answer for a patient inside DC and a patient outside of DC? <p>Mifepristone, because of risks, is under an FDA program (REMS) which requires the prescriber and dispenser to be registered in the program in order to prescribe or dispense this medication. DC does not have any laws or regulations that would impose any additional restrictions, other than the</p>	<p>AN</p>

requirement that the pharmacy be licensed in DC, either as an in state pharmacy or a nonresident pharmacy.



Mifepristone (generic) /Mifeprex (brand) is not a controlled substance but has some additional requirements by the FDA. The requirements are outlined in a [Risk Evaluation and Mitigation Strategy \(REMS\)](#). An overview of the requirements is as follows:

- Mifepristone must be prescribed by or under the supervision of a certified healthcare provider who meets certain qualifications, including signing a Prescriber Agreement Form;
- The healthcare provider must obtain a signed Patient Agreement Form from the patient after counseling and prior to prescribing Mifeprex.
- Pharmacies that dispense Mifepristone must be certified.

The Pharmacy Control Division at DC Health has confirmed the medication can be mailed into the District just as long as the pharmacy is licensed in the District of Columbia and certified to dispense the product. Similarly, a DC Pharmacy can mail the medication to an individual in the District; mailing it to someone outside of the District will depend on that state's laws (the state where the patient is located).

Please note the REMS link references that the product can only be dispensed in certain healthcare settings (specifically clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber). As of December 2021, this was changed to reduce the burden on patient access. "Removing the in-person dispensing requirement will allow, for example, dispensing of mifepristone by mail via certified prescribers or pharmacies, in addition to in-person dispensing in clinics, medical offices, and hospitals as currently outlined in the Mifepristone Rems Program." (<https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifeprex-Q#6>, last accessed July 1, 2022).

<https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rem#:~:text=A%20Risk%20Evaluation%20and%20Mitigation,the%20medication%20outweigh%20its%20risks.>

	 <p>Risk Evaluation and Mitigation Strategies REMS FDA A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ... www.fda.gov</p>	
	<p>https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information</p>	
	 <p>Mifeprex (mifepristone) Information FDA Mifeprex (mifepristone) is used, together with another medication called misoprostol, to end an early pregnancy. FDA first approved Mifeprex in 2000. www.fda.gov</p>	
<p>OS-22-07-09 ALL</p>	<p><u>FEDERATION OF STATE MEDICAL BOARDS (FSMB) ANNUAL REPORT- FYI</u></p> <p>Board Action: Informational purposes only.</p> <p>Background: FSMB 2022 annual report regarding “Messaging and Partnership, Advancing Ideas Through Collaboration.</p>	

The Open Session Agenda continues on the next page with ‘Motion to Close’.

MOTION TO CLOSE

OS-22-07-10	<u>MOTION TO CLOSE</u>	AN
ALL	<p>Board Action: To go into closed session to discuss confidential matters as permitted in DC Official Code § 2-575(b).</p> <p>Background: Pursuant to DC Official Code § 2-575(b), the Board will move into the Closed Executive Session portion of the meeting to discuss the following:</p> <ol style="list-style-type: none">1. To consult with an attorney to obtain legal advice and to preserve the attorney-client privilege between an attorney and a public body, or to approve settlement agreements pursuant to § 2-575(b)(4)(a);2. Preparation, administration, or grading of scholastic, licensing, or qualifying examinations pursuant to section § 2-575(b)(6);3. To discuss disciplinary matters pursuant to section § 2-575(b)(9);4. To plan, discuss, or hear reports concerning ongoing or planned investigation of alleged criminal or civil misconduct or violations of law or regulations, if disclosure to the public would harm the investigation pursuant to section § 2-575(b)(14).	

The Open Session Agenda continues on the next page with ‘Motion to Adjourn’.

MOTION TO ADJOURN		
OS-22-07-11	<u>MOTION TO ADJOURN</u>	AN
ALL	<p>Board Action: To adjourn the meeting.</p> <p>Background: At the end of every meeting, a motion to adjourn must be made in open session to close out the business of the Board.</p>	

This ends the Open Session Agenda.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.

